The FDA says it finalized a new rule that will allow more gay and bisexual men to donate blood.
, all potential donors would need to complete an individualized risk assessment — regardless of gender or sexual orientation. People who have had anal sex with a new partner, or more than one partner, in the last three months would be asked to wait to donate blood.
The updated guidelines mean most gay and bisexual men who are in a monogamous relationship with another man will no longer need to abstain from sex to donate blood.from men who have sex with men if they hadn't had sex with another man for three months. “The implementation of these recommendations will represent a significant milestone for the agency and the LGBTQI+ community,” Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a release.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA finalizes blood-donation rules to allow more gay, bisexual menThe updated FDA guidelines do away with a requirement that men who have sex with men abstain from sex for three months prior to giving blood.
Les mer »
FDA Eases Restrictions on Blood Donations, Allowing More Gay Men to Give in USGay and bisexual men in monogamous relationships can donate blood in the U.S. without abstaining from sex, under a federal policy finalized Thursday by health regulators.
Les mer »
FDA Begins Allowing More Gay, Bisexual Men to Donate BloodThe Food and Drug Administration has finalized blood-donation rules that will allow more gay and bisexual men to donate blood
Les mer »
‘Caught between a rock and a hard place’: FDA considers over-the-counter birth controlThe agency is slated to make a decision on approval of the daily hormonal pill by this summer.
Les mer »
FDA approves ALS treatment for patients with genetic diseaseThe FDA has fast-tracked a new ALS treatment for patients whose disease is genetic. Patients who have been getting the injections report a slowing of their disease progression and even renewed strength.
Les mer »
FDA Expands Use of Dapagliflozin to Broader Range of HFThe SGLT2 inhibitor is now indicated for treatment of heart failure across the full spectrum of left-ventricular ejection fraction ― including HF with mildly reduced and preserved ejection fraction.
Les mer »